Effects of long-term diabetes and/or high-dose 17β-estradiol on bone formation, bone mineral density, and strenght in ovariectomized rats

Abstract

Long-term diabetes in female rats preserves the bone mineral density (BMD) but impairs the strength of the femur. In this study, we have compared the effects of diabetes and high-dose 17β-estradiol (E 2), two conditions of low bone formation, in ovariectomized (ovx) rats. Spontaneously diabetic BB rats were ovx 0–3 days after onset, and nondiabetic ovx littermates were used as controls; the rats were either untreated or treated with E 2 (30 μg/day), subcutaenously), for 6 or 12 weeks (n = 9 in each of the eight groups). Analysis included: plasma 1,25-dihydroxyvitamin D 3, insulin-like growth factor-I (IGF-I), and osteocalcin concentrations; histomorphometry of the proximal tibial metaphysis (PTM); and DXA and biomechanical testing of the femur. Both E 2 treatment and diabetes markedly lowered plasma IGF-I and osteocalcin concentrations, as well as dynamic morphometric parameters of bone formation in the PTM. Plasma IGF-I and osteocalcin were correlated ( R 2 = 0.55; p < 0.0001). E 2 treatment in both control and diabetic ovx rats increased the trabecular bone volume in the PTM and the BMD in the metaphysis of the distal femur; there was no difference between control and diabetic rats, however. The diaphyseal area and BMC were decreased in E 2-treated or/and diabetic ovx rats, but the diaphyseal BMD remained unchanged compared with untreated ovx rats. The biomechanical properties of the whole femur (strength, angular deformation, and stiffness) were decreased in E 2-treated and diabetic E 2-treated ovx rats after 12 weeks. The data indicate that in situations of chronic low bone formation, whole bone strenght does not reflect total BMD but correlates better with bone size and bone mineral content measurements.